

1 Research paper

2 **Study of Fluconazole Release From O/W Cream and Water Soluble Ointment**
3 **Bases**

4 Aml Mekkawy¹, M. Fathy¹, Sohair El-Shanawany¹

5 ¹ Department of Pharmaceutics, Faculty of Pharmacy, Assuit University, Assuit, Egypt

6 **Correspondence to:**

7 Aml Mekkawy, E-mail: dr_amola85@yahoo.com, Telephone Number: 00201009610197, Fax:

8 0020882332776, Postal code: 71515

9

10

11

12

13

14

15

16

17

18

19

20 **Abstract**

21 Aims: Study the difference in release of fluconazole from O/W cream and PEG ointments.

22 Study Design: In this study i prepared different formulation with changing one of the excipients
23 and study the effect of this change on the release of fluconazole. Then the best one formulation of
24 each dosage form will be subjected to antifungal activity study.

25 Place and Duration of Study: Faculty of Pharmacy, Department of Pharmaceutics, Assiut
26 University, between December 2011 and March 2012.

27 Methodology: O/W creams were prepared with changing the type of fatty alcohol and the
28 concentration of the emulsifying agent. Also, PEG ointments were prepared with changing the type
29 of the liquid PEG (low molecular weight) and study the effect of those changes on the formulation
30 viscosity and fluconazole release.

31 Results: changing the fatty alcohol type from stearyl to cetostearyl and cetyl alcohol in the O/W
32 creams caused an increase in the viscosity and a decrease in the drug release. Also, changing the
33 liquid PEG from PEG 400 to PEG 600 resulted in an increase in the formulation viscosity and
34 subsequent decrease in the drug release. Both F1 and F6 showed a good inhibition to the fungal
35 growth against *Candida albicans* and *Trichophyton mentagrophyte* using cup plate method, also
36 PEG base showed a slight fungal growth inhibition.

37 Conclusion: Results obtained showed that the PEG ointment formulations showed better
38 fluconazole release over the O/W cream formulations. For PEG ointments, the nature of the base
39 itself may be adjunctive to the efficacy of the antifungal agent

40 **Keywords:** Fluconazole; O/W creams; Fatty alcohol; Poly Ethylene Glycols; in vitro
41 release; kinetics; antifungal activity.

42 **Abbreviations:** Fluconazole (FLZ), Poly Ethylene Glycols (PEG), Oil in water Creams
43 (O/W Creams), Propylene Glycol (PG), Polyethylene Glycol 4000 (PEG 4000), Polyethylene Glycol
44 600 (PEG 600).

45 **1. INTRODUCTION**

46 Topical products for the treatment of dermatological diseases include a wide choice of vehicles
47 ranging from solids to semisolids and liquid preparations including creams, gels, ointments, pastes,
48 aerosols and solutions.

49 cream and ointment are topical formulations offer better patient compliance and hence become more
50 acceptable to patients [1]

51 Cream is an emulsion semisolid dosage form that contain > 20 % water and volatiles and/or < 50%
52 hydrocarbons, waxes or polyethylene glycols as the vehicle for external application to the skin[2].

53 There are two types of creams; an oil-in-water cream with the water as the continuous phase and a
54 water-in-oil cream with oil as the continuous phase. Creams are opaque, viscous and non-greasy to
55 mildly greasy, tend to mostly evaporate or be absorbed when rubbed onto the skin. Generally, cream is
56 preferred by many investigators in azole group with different formulations [3-5].

57 Petrolatum jelly (White soft paraffin) is used as a base material in formulating ointment and creams.

58 It is a mixture of solid and liquid hydrocarbons and is solid-like at room temperature [6]. Some solid
59 aliphatic fatty alcohols like stearyl alcohol, cetyl alcohol and cetostearyl alcohol are reported to be
60 used in oil-in-water emulsions to form a viscoelastic continuous phase in combination with the
61 aqueous emulsifier solution that impart semisolid properties to the emulsion and prevent droplet
62 coalescence and hence increase its stability. Stearyl alcohol is 1-octadecanol (C18), cetyl alcohol is
63 1-hexadecanol (C16) and cetostearyl alcohol consists mainly of a mixture of them in which stearyl
64 alcohol consists about 50-70 % and cetyl alcohol consists about 20-35 % [7]. Variations in these
65 base materials lead to variability in cream formulation in an attempt to achieve the optimum high

66 quality topical drug. Different investigations on cream formulations on different drugs are carried
67 out in this concern [3, 5, 8, 9].

68 Different formulations of azole antifungal ointment are postulated by different authors [3-5]. It is a
69 semisolid dosage form that contains < 20% water and volatiles and > 50 % hydrocarbons, waxes or
70 polyethylene glycols as the vehicle for external application to the skin. They are opaque or
71 translucent, viscous, greasy; they don't tend to evaporate or be absorbed when rubbed onto the skin.
72 Hydrocarbon bases (oleaginous ointment bases), absorption bases and water soluble bases
73 (greaseless ointment bases) are different types of ointment base. This variability of base materials
74 facilitates the production of optimum formulation. In water soluble bases, polyethylene glycol
75 ointment is the only pharmacopeial preparation. Polyethylene glycols (PEGs) known also as
76 macrogols are widely used in topical pharmaceutical formulations since these chemicals are stable,
77 hydrophilic substances that are essentially nonirritant to the skin and easily removed from the skin
78 by washing. In research, authors are trying to obtain optimum release of topically applied drug to
79 increase the bioavailability and obtain a better therapeutic effect with maintaining aesthetically
80 acceptable formulations for patient and be easily used and adhere to the treated area in the required
81 time with good physical and chemical stability.

82 **2. MATERIALS AND METHODS**

83 **2.1. Materials**

84 Fluconazole (FLZ.) was kindly provided by CIDCO, Cairo, Egypt. The Spectra/Por® dialysis
85 membrane 12000 to 14000 molecular weight cut off (Spectrum Laboratories Inc., USA). propylene
86 glycol (PG), white soft paraffin, anhydrous lanolin, bees wax, stearyl alcohol, Tween 80,
87 polyethylene glycol 4000 (PEG 4000), polyethylene glycol 600 (PEG 600) (Adwic, EL-Nasr
88 Pharmaceutical Chemicals Co., Egypt). Sodium hydroxide pellets (EL-Gomhouria Co., Egypt).
89 Polyethylene glycol 400 (PEG 400) (LOBA CHEMIE PVT. LTD. Mumbai, India). Liquid paraffin,

90 cetyl alcohol and cetostearyl alcohol (ISO-CHEM, Egypt). Organisms: Candida albicans No 11 &
 91 Trichophyton mentagrophyte No 5500 (supplied from Mycological center, Faculty of Science,
 92 Assiut University).

93 **2.2. Preparation of fluconazole gel formulations.**

94 The composition of the prepared ointment and cream formulation bases containing 1 % w/w
 95 fluconazole is shown in table 1

96 **Table 1:- Composition of the prepared ointment and cream formulations containing 1 % fluconazole.**

Composition	O/W emulsified bases (O/W creams)					PEG ointment bases	
	F1	F2	F3	F4	F5	F6	F7
White soft paraffin	10	10	10	10	10		
Liquid paraffin	10	10	10	10	10		
Propylene glycol	20	20	20	20	20	20	20
Stearyl alcohol	20			20	20		
Cetostearyl alcohol		20					
Cetyl alcohol			20				
Tween 80	2	2	2	4	6		
Water	38	38	38	36	34		
Polyethylene glycol 4000						20	20
Polyethylene glycol 400						60	
Polyethylene glycol 600							60

97

98 **2.2.1. Preparation of o/w emulsion ointments (o/w creams).**

99 White soft paraffin and the fatty alcohol used (stearyl alcohol, cetostearyl alcohol or cetyl alcohol)
 100 were melted in a porcelain dish over a boiling water bath. Liquid paraffin (if present) was heated to
 101 approximately the same temperature and added to the melted base. Fluconazole (1% w/w) dissolved
 102 in 20 % propylene glycol and the specified concentration of tween 80 was added to the calculated

103 amount of water. Both the aqueous and the oily phases were heated to 70°C. The oily phase then
104 was added gradually to the aqueous phase with continuous stirring until the o/w cream was formed.

105

106 **2.2.2. Preparation of water soluble ointments.**

107 The specified concentration of polyethylene glycol (PEG) 4000 was melted over a boiling water
108 bath. PEG 400 or PEG 600 was heated to approximately the same temperature and added. The
109 mixture was then removed from heat and stirred. Then, fluconazole (1% w/w) dissolved in 20 %
110 propylene glycol (which is slightly heated) was added to the PEGs mixture and stirred until
111 congealing.

112 **2.3. Evaluation of the prepared fluconazole gel formulations.**

113 **2.3.1. Viscosity.**

114 The viscosity of the prepared gel formulations was determined using BrookField DV-III ULTRA
115 programmable rheometer, model RV, helipath spindle set (Brookfield Engineering laboratories,
116 USA) using T-bar spindle. The viscosity was measured at temperature 25°C using 20g sample. This
117 experiment was performed for both the plain and the medicated formulations.

118 **2.3.2. *In vitro* release studies**

119 The *in vitro* release of fluconazole from the prepared formulations was studied using dialysis
120 method. A one gram sample of each formulation was accurately weighed and placed on a semi
121 permeable cellophane membrane (previously immersed in phosphate buffer pH 7.4 for 24 hours) to
122 occupy a circle of 2.5 cm diameter. The loaded membrane (donor compartment) was firmly
123 stretched over the lower open end of a glass tube of 2.5 cm internal diameter and made watertight by
124 rubber band. The tube was then immersed in a beaker containing 25 ml of phosphate buffer pH 7.4
125 which is the release medium (receptor compartment). The system was maintained for 3 hours at 37
126 $\pm 0.5^\circ\text{C}$ in a thermostatic shaking water bath at 50 rpm. Samples of 5 ml were withdrawn at intervals

127 of 0.25, 0.5, 0.75, 1, 1.5, 2, and 3 hours. The volume of each sample was replaced by the same
 128 volume of fresh buffer (kept at the same temperature) to maintain constant volume. Samples were
 129 analyzed for fluconazole content spectrophotometrically at λ_{max} 261 nm against blank similarly
 130 treated.

131 2.3.3. Analysis of the release data

132 The release mechanisms of fluconazole from the semisolid formulations were elucidated by
 133 fitting the release data to four kinetic models. Regression analysis was adopted to compute the
 134 constants and correlation of data (r^2).

135 Zero order kinetics

$$136 \quad Q = k_0 t \quad [10] \quad (1)$$

137 Where Q is the % of drug released at time t , k_0 is the zero order release constant and t is the
 138 time in hours.

139 First order kinetics

$$140 \quad \ln(100-Q) = \ln 100 - k_1 t \quad [10] \quad (2)$$

141 Where K_1 is the first order release constant.

142 Higuchi kinetics

$$143 \quad Q = k_H t^{1/2} \quad [11] \quad (3)$$

144 Where Q is the amount of drug released at time t per unit area & K_H is the Higuchi release rate
 145 constant.

$$146 \quad K_H = 2C_0 (D/\pi)^{1/2} \quad (4)$$

147 Where C_0 is the initial drug concentration & D is the diffusion coefficient.

148 Korsmeyer peppas equation

$$149 \quad M_t/M_\infty = kt^n \quad [12] \quad (5)$$

150 Where M_t/M_∞ is the fraction of released drug at time t & n is the release exponent.

151 n value is indicative for the drug release mechanism, If $n \leq 0.5$ it is a fickian diffusion
152 mechanism, $0.5 < n < 1$ it is a non-fickian mechanism (anomalous diffusion) and if $n = 1$, so release
153 mechanism from the formulation follows a zero order mechanism (case-2 relaxation). In case of $n >$
154 1, it indicates a super case-2 transport. Anomalous diffusion or non-fickian diffusion refers to
155 combination of both diffusion and erosion controlled release rate while case-2 relaxation and super
156 case-2 transport refer to erosion of the polymeric chain.

157 **2.3.4. Statistical analysis.**

158 All studies were performed in triplicate and the values were expressed as mean \pm S.D. The data
159 were analyzed by one way ANOVA and Post Hoc Turkey-Test at a significance level of .05,
160 homogeneity of variance was evident by Levene's test in most cases and assumed in few others
161 since no transformations were valid. Student T-test was also considered in some cases at a
162 significance level of .05. SPSS statistical package [13] was used in these analyses.

163 **2.3.5. *In vitro* antifungal activity**

164 Agar cup-plate method was adopted for this study. The *in vitro* antifungal activity of the selected
165 O/W cream (F1) and PEG ointment (F6) fluconazole formulation against *Candida albicans* (as a
166 representative Yeast fungus) and *Trichophyton Mentagrophyte* (as a representative Dermatophyte
167 fungus) was studied. A single isolate of each fungus was picked from the agar slab culture to
168 prepare spores suspensions in sterile water and was adjusted to be 1×10^6 spores/ml. One ml of the
169 spores' suspension was mixed with Sabouraud agar (15-20 ml) in sterile Petri dish (9 cm in
170 diameter) and the agar plates were allowed to solidify. After solidification, a single well was made
171 in each agar plate using a porer of size 1 cm and filled with an accurately weighed 0.5 gm of each
172 formula (either medicated or plain).The plates were incubated at $25 \pm 1^\circ\text{C}$ for 3 days (for *Candida*
173 isolates) and 8 days (for *Trichophyton* isolates) and then they were examined for the inhibition zone
174 diameter which is an indicator for the antifungal activity. Plain formulations (without drug) were


175 also tested as a positive growth control result. The mean value of the inhibition zone diameter from
 176 three plates was calculated.

177 **3. RESULT AND DISCUSSION**

178 **3.1. Evaluation of the prepared fluconazole gel formulations:-**

179 **3.1.1. Viscosity.**

180 The viscosity of the prepared formulations is illustrated in figure 1. The viscosity differed according
 181 to the change in type of fatty alcohol and concentration of added Tween 80 (for O/W creams) and the
 182 molecular weight of the liquid polyethylene glycol (for PEG ointments).



183
 184 Fig.1. Viscosity of different ointment and cream formulations at 10 rpm at 37°C


185
 186 As shown, formulations F3 containing cetyl alcohol exhibited higher viscosity over F2 containing
 187 cetostearyl alcohol and F1 containing stearyl alcohol. The effect of increasing the added percent of
 188 Tween 80 from 2 % to 6 % w/w on the viscosity of the prepared o/w cream containing 20 % w/w
 189 stearyl alcohol (F1) was studied. It is obviously clear that increasing the Tween 80 concentration
 190 resulted in a large increase in the viscosity of the formulations. Therefore, the viscosity of F5
 191 containing 6 % w/w T80 was much higher than F4 containing 4 % w/w T80 and F1 containing 2 %
 192 w/w T80. Similar results were obtained by Patel et al. [14] who found that increasing the

193 concentration of the emulsifying agent in the psoralen cream formulation led to increased viscosity of
 194 the formulation. In case of PEG ointment formulations, the viscosity of was increased with increasing
 195 the molecular weight of the liquid PEG used. So, F7 containing PEG 600 exhibited higher viscosity
 196 over F6 containing PEG 400.

197 **3.1.2. *In vitro* release studies.**

198 The percent of fluconazole released over a period of three hours from the prepared ointment and
 199 cream formulations containing 1 % w/w fluconazole is shown and discussed as follow:

200 Figures 2 & 3 show the release data of FLZ from the prepared o/w cream formulations where the type of
 201 fatty alcohol and the percentage of the emulsifying agent (Tween 80) were varied.



202

203

Fig.2. Effect of different fatty alcohols on the fluconazole release from O/W creams

204




Fig.3. Effect of Tween 80 concentration on the fluconazole release from O/W creams


205

206

207

208 As noticed from figure 2, F1 containing stearyl alcohol exhibited significantly ($p < 0.05$) higher release
 209 of FLZ over F2 containing cetostearyl alcohol and F3 containing cetyl alcohol. Halpern and Zope[15]
 210 studied the hydrophilic properties of the ointment base constituents. They reported that stearyl alcohol
 211 caused the greatest potentiating effect on water number of petrolatum over cetyl alcohol and other
 212 studied fatty alcohols. Accordingly, the presence of stearyl alcohol increased the hydrophilic properties
 213 of these formulations over those containing cetostearyl alcohol and cetyl alcohol. This increased the
 214 affinity of the base to absorb water from the release medium and subsequently increased the drug
 215 diffusion and release. Cetostearyl alcohol exhibited higher release over cetyl alcohol as stearyl alcohol
 216 represents about 70 % w/w of its constituents. These results are also attributed to the higher viscosity of
 217 formulations F3 containing cetyl alcohol over formulations F2 and F3 containing cetostearyl and stearyl
 218 alcohols, respectively. Figure 3 shows the effect of increasing the concentration of Tween 80 from 2%
 219 to 6 % w/w on the FLZ release from o/w cream containing 20 % w/w stearyl alcohol and 10 % w/w
 220 liquid paraffin. It was found that the release of the drug from F5 containing 2 % w/w Tween 80 was
 221 insignificantly ($p > 0.05$) higher than F10 & F11 containing 4 % and 6 % w/w Tween 80, respectively.
 222 This might be attributed to the higher viscosity of the formulations upon increasing the Tween 80
 223 concentration.

224 Release profile of fluconazole from water soluble ointment bases is illustrated in figure 4. It shows
 225 that the FLZ release from PEG ointments was higher than that from the O/W creams (o/w
 226 emulsified ointments). This finding was due to the high solubility of the drug in PEG base. De
 227 Muynck and Remon [3] also reported that polyethylene glycol ointment has shown the highest
 228 release rate of metronidazole compared to o/w emulsion. The formulation F6 containing low
 229 molecular weight PEG 400 exhibited a higher drug release over F7 containing higher molecular
 230 weight PEG 600, respectively. These results can be explained by the reduced viscosity of the
 231 formulation upon using lower molecular weight PEGs.



232
 233 Fig.4. Effect of the liquid PEG molecular weight on the fluconazole release
 234 from PEG ointment formulations.

235
 236 In conclusion, the diffusion of any drug through the different bases depends on the nature and the
 237 composition of the bases and the release rate can be altered by changing the nature and the
 238 composition of the bases.

239 **3.1.3. Analysis of the release data**

240 The kinetic analysis of the in vitro release data of FLZ from all the prepared formulations is
 241 presented in table 2. The preference between the release mechanisms was dependent on the

242 coefficient of determination (R^2 ; squared correlation coefficient) and the release exponent (n) of
 243 korsmeyer-peppas equation. As shown in the table, R^2 and n values ($0.5 < n < 1$) indicated that the
 244 release of FLZ from O/W emulsified formulations followed first order kinetics and was based on
 245 non-fickian diffusion. While the drug release from water soluble ointment bases followed zero order
 246 kinetics with n values = 1 indicating a case-2 relaxational release for F6 and $n > 1$ indicating super
 247 case -2 transport for F7. In both cases, this refers to erosion of the polymeric chain.

248

249 Table 2. Kinetic analysis of the release data of fluconazole from prepared formulations

Formula		Zero Order		First Order			Higuchi Diffusion model				Korsmeyer-peppas	
		R^2	K_0 (% h ⁻¹)	R^2	K_1 (h ⁻¹)	$T_{0.5}$ (h)	Q/A vs. T ^{1/2}		Ln Q/A vs. Ln T		R^2	n (slope)
							R^2	D	R^2	n (slope)		
o/w cream	F1	0.973	14.454	0.994	0.192	3.604	0.836	0.001	0.702	0.820	0.473	0.823
	F2	0.882	10.546	0.927	0.133	5.229	0.857	0.001	0.574	0.532	0.247	0.535
	F3	0.981	8.747	0.990	0.101	6.887	0.803	0.000	0.619	1.331	0.471	1.335
	F4	0.927	11.964	0.965	0.154	4.488	0.854	0.001	0.634	0.579	0.302	0.583
	F5	0.921	12.188	0.958	0.157	4.418	0.851	0.001	0.669	0.659	0.360	0.663
Water soluble base	F6	0.997	20.743	0.989	0.315	2.198	0.796	0.002	0.825	1.023	0.628	1.026
	F7	0.987	20.116	0.955	0.292	2.377	0.725	0.002	0.829	1.477	0.678	1.480

250

251 R2: Coefficient of determination, Ko: Zero order release constant, K1: First order release constant, T0.5: Half-life of
 252 first-order reaction,D: Diffusion coefficient.

253

254 **3.1.4. In-vitro antifungal activity**

255 The results of the selected medicated formulations of the prepared ointments (F6) and creams (F1)
 256 that subjected to antifungal activity are described in table 3 and the growth inhibition zones are
 257 shown photographically in figures 4 & 5.

258

259 Table.3. *In vitro* antifungal activity of the selected medicated and plain formulations using two
 260 different fungal isolates by agar-diffusion method.


261

Type of formula	Type of fungi and isolate number	
	<i>Candida albicans</i> *	<i>Trichophyton mentagrophyte</i> **
	No:11	No:5500
	Average diameter of growth inhibition zone (mm) ± SD	
Medicated cream (F1)	45.0 ± 5.00	50.0 ± 5.00
Medicated ointment (F6)	48.3 ± 2.89	51.7 ± 2.89
Plain cream	0	0
Plain ointment	Not well marked	Not well marked

**Candida albicans* No: 11 was isolated from patient with *Tinea capitis*


***Trichophyton mentagrophyte* No: 5500 was isolated from patient with *Tinea pedis*

262



263

264 Fig.5. The growth inhibition zone of the medicated cream (F1) against (a) *Candida albicans* & (b)
 265 *Trichophyton mentagrophyte*.



266

267 Fig.6. The growth inhibition zone of the medicated PEG ointment (F6) against (a) *Candida*
268 *albicans* & (b) *Trichophyton mentagrophyte*

269 As illustrated in table 3 and figures 4 & 5, the tested formulations exhibited a good growth
270 inhibition zone for the tested fungal isolates. It was found that the plain formulation of F1 have
271 showed a normal fungal growth in the agar plates. So, excipients used have no growth inhibitory
272 effect on the tested fungi. In contrast, the plain polyethylene glycol (F6) ointment showed some
273 growth inhibition to the tested fungi. This might be due to the PEG effect on the water activity in
274 the culture medium. Similar results were obtained by Inch and Trinci [16] who found that PEG 200
275 is inhibitory to *Paecilomyces farinosus* because of its effect on water activity. They mentioned also
276 that there was a linear relationship between the decrease in the water activity of the medium and the
277 decrease in the growth yield. The inhibitory effect was more pronounced in the *Trichophyton*
278 isolates than the *Candida* isolates. Klipp [17] mentioned that the pathogen *Candida albicans* can
279 adapt to different environmental conditions such as osmotic changes. This ability plays an important
280 role in the fungus virulence. The osmoadaptive response is not identical in different fungi and the
281 fungus ability to survive depends on its capability to alter the morphogenic programs[18]. Gleason
282 et al. [19] predicted different fungal growth response according to the different water potential.
283 With increasing the water potential, the fungus may not be affected until the response mechanisms
284 are overwhelmed and growth ceases or the growth of the fungus may slow or the fungus may be

285 adapted to this high water potential and the growth will increase until the response mechanisms are
286 overwhelmed.

287 **Conclusion**

288 Results obtained showed that the PEG ointment formulations showed better fluconazole release
289 over the O/W cream formulations. For PEG ointments, the nature of the base itself may be
290 adjunctive to the efficacy of the antifungal agent. So, PEG bases could be with further
291 investigations a promising topical antifungal agent.

292 **References**

- 293 [1] David A.O.and Anton H.A. (eds.) Topical Drug Delivery Formulations, Marcel Dekker, Inc., New
294 York, NY, USA, 1990.
- 295 [2] Srivastava P. - Excipients for Semisolid Formulations -, In: Excipient development for
296 pharmaceutical, biotechnology, and drug delivery systems, A. Katdare and M.V. Chaudhary (eds.),
297 Informa Healthcare, 2006, pp. 197-224.
- 298 [3] De Muynck C. and Remon J.P. - Stability, *in vitro* and *in vivo* release studies from metronidazole
299 ointments.- Drug Dev Ind Pharm, 13,1483-1493, 1987.
- 300 [4] Ismail S., Mohamed A.A., and Abd El-Mohsen M.G. - *In vitro* release of sulconazole nitrate from
301 ointment bases.- Bull Pharm Sci, Assuit University, 13,115-123, 1990.
- 302 [5] Shivanand P., Devmurari V., Manish G., and Pandey D. - Formulation, optimization and *in vitro*
303 evaluation of ketoconazole cream.- Der Pharmacia Lettre, 1,18-24, 2009.
- 304 [6] Park E.-K. and Song K.-W. - Rheological evaluation of petroleum jelly as a base material in ointment
305 and cream formulations with respect to rubbing onto the human body.- Korea-Aust Rheol J,
306 22,279-289, 2010.
- 307 [7] Rowe R.C., Sheskey P.J., and Owen S.C. (eds.) Handbook of pharmaceutical excipients,
308 Pharmaceutical Press and American Pharmacists Association, 2006.
- 309 [8] Al-Kubati S.S.F. Formulation and evaluation of nimesulide in some topical pharmaceutical dosage
310 form, Vol. PhD-Thesis, Assuit university, Assuit, Egypt, 2011.
- 311 [9] Sepulveda E., Kildsig D.O., and Ghaly E.S. - Relationship between internal phase volume and
312 emulsion stability: the cetyl alcohol/stearyl alcohol system.- Pharm Dev Technol, 8,263-275,
313 2003.
- 314 [10] Xu G.J. and Sunada H. - Influence of formulation changes on drug release kinetics from
315 hydroxypropyl methylcellulose matrix tablets.- Chem Pharm Bull (Tokyo), 43,483-487, 1995.
- 316 [11] Higuchi T. - Mechanism of rate of sustained-action medication. Theoretical analysis of rate of solid
317 drugs dispersed in matrices.- J Pharm Sci, 52,1145-1149, 1963.
- 318 [12] Ritger R.L. and Peppas N.S. - A simple equation for disposition of solute release II: Fickian and
319 anomalous release from swellable devices.- J Controlled Release, 5,37-42, 1987.
- 320 [13] SPSS. SPSS for windows, Release 17.0.0, SPSS Inc, 2008.
- 321 [14] Patel N.A., Patel N.J., and Patel R.P. - Comparative development and evaluation of topical gel and
322 cream formulations of psoralen.- Drug Discov Ther, 3,234-242, 2009.
- 323 [15] Halpern A. and Zope L.C. - Hydrophilic properties of certain ointment base constituents.- J Am
324 Pharm Assoc (Wash), 36,101-104, 1947.
- 325 [16] Inch J.M.M. and Trinci A.P.J. - Effects of water activity on growth and sporulation of *paecilomyces*
326 *farinosus* in liquid and solid media.- J Gen Microbiol, 133,247-252, 1987.

- 327 [17] Klipp E. (ed.) Modelling of regulatory networks responsible for candida albicans virulence,
328 FINSysB Marie Curie Initial Training Network, 2011.
- 329 [18] Duran R, Cary J.W., and Calvo A.M. - Role of the osmotic stress regulatory pathway in
330 morphogenesis and secondary metabolism in filamentous fungi.- *Toxins*, 2,267-381, 2010.
- 331 [19] Gleason F.H., Midgley D.J., Letcher P.M., and McGee P.A. - Can soil Chytridiomycota survive and
332 grow in different osmotic potentials?- *Mycol Res*, 110,869-875, 2006.

334

335

336

337